MBB Public Markets I LLC Takes $1.08 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

MBB Public Markets I LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,386 shares of the biotechnology company’s stock, valued at approximately $1,079,000.

Several other institutional investors have also modified their holdings of UTHR. TD Asset Management Inc lifted its stake in shares of United Therapeutics by 1,066.4% in the 4th quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock valued at $18,240,000 after purchasing an additional 75,839 shares during the last quarter. Allianz Asset Management GmbH lifted its stake in shares of United Therapeutics by 8.6% in the 4th quarter. Allianz Asset Management GmbH now owns 30,267 shares of the biotechnology company’s stock valued at $6,655,000 after purchasing an additional 2,409 shares during the last quarter. Bank of Nova Scotia lifted its stake in shares of United Therapeutics by 713.8% during the 4th quarter. Bank of Nova Scotia now owns 24,879 shares of the biotechnology company’s stock worth $5,470,000 after acquiring an additional 21,822 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of United Therapeutics by 1.3% during the 4th quarter. California State Teachers Retirement System now owns 73,248 shares of the biotechnology company’s stock worth $16,107,000 after acquiring an additional 957 shares during the last quarter. Finally, APG Asset Management US Inc. bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $1,938,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on UTHR. Jefferies Financial Group raised their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. Finally, UBS Group raised their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $357.17.

United Therapeutics Price Performance

UTHR opened at $358.35 on Tuesday. The firm has a market capitalization of $15.89 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 1.30 and a beta of 0.57. The business’s 50-day moving average is $342.59 and its two-hundred day moving average is $296.92. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the firm earned $5.24 EPS. Research analysts anticipate that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $40,622.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 107,652 shares of company stock worth $35,785,807. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.